Where does Antisense Therapeutics Ltd rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Antisense Therapeutics Ltd ranks #28,086 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Antisense Therapeutics Ltd hold?

Antisense Therapeutics Ltd holds 9 US utility patents granted between 2015 and 2024, spanning 6 technology areas.

What is Antisense Therapeutics Ltd's Innovation Score?

Antisense Therapeutics Ltd has an Innovation Score of 39.3 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Antisense Therapeutics Ltd's patent grant rate increasing or decreasing?

Antisense Therapeutics Ltd's recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Antisense Therapeutics Ltd's patents?

Antisense Therapeutics Ltd's patents average 15.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Antisense Therapeutics Ltd patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Antisense Therapeutics Ltd

Q: What technology areas does Antisense Therapeutics Ltd focus on?

Antisense Therapeutics Ltd's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 9 patents. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Antisense ranks #28,086 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 6 technology areas.

#28,086
of 49,997 US assignees by volume: Top 38%
by Innovation Score (39.3/100): 15.6
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R28086 · Foreign Corporation #28,086 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #28,086/49,997
PHOTO-FINISH Anji Leisa Furniture
CPC-NARROW A61P · 6 areas
INNOV-THIN 39.3/100
CLAIMS-RICH 15.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Anji Leisa Furniture Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Antisense Therapeutics · this assignee

39
3D Lighting… · lowest

7

What this shows Antisense's Innovation Score is 39.3/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Antisense's grants concentrate

Antisense Therapeutics Ltd is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2015. By volume, Antisense sits between Anji Leisa Furniture Co., Ltd. and Applied Software Technology, Inc..

Antisense's three-year grant acceleration

Antisense Therapeutics Ltd shows 2 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Anji Leisa Furnit…

9
Anji Weiyu Furnit…

9
Annexon

9
Ansorg

9
Aphios

9
Apogee Enterprises

9
Appalachian Light…

9
Applied Software…

9
Antisense Therape… ◀

9

What this shows Antisense holds 9 patents at rank #28,133, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Antisense

By rank, the assignees closest to #28,133 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Antisense's primary technology class.

Antisense's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 38% higher than 62% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Antisense Therapeutics Ltd patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	11.1%
2016	1	11.1%
2017	2	22.2%
2018	2	22.2%
2021	1	11.1%
2024	2	22.2%

Which technologies does Antisense Therapeutics Ltd patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

Y10T - Technical Subjects Covered BY Former US Classification 2

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#28,086

of 49,997 tracked assignees

Innovation Score

39.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Antisense Therapeutics Ltd's patent record in context - here's where to go next.

Antisense Therapeutics Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #28,086 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Antisense Therapeutics Ltd against Anji Leisa Furniture Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.